BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37532840)

  • 1. Feasibility of individualised patient modelling for continuous vancomycin infusions in outpatient antimicrobial therapy, a retrospective study.
    Nolan J; McCarthy K; Farkas A; Avent ML
    Int J Clin Pharm; 2023 Dec; 45(6):1444-1451. PubMed ID: 37532840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-Resistant
    Song X; Han M
    Front Cell Infect Microbiol; 2022; 12():874401. PubMed ID: 35873144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.
    Flannery AH; Delozier NL; Effoe SA; Wallace KL; Cook AM; Burgess DS
    Pharmacotherapy; 2020 Dec; 40(12):1210-1218. PubMed ID: 33176005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the mathematical equation and trapezoidal approach for 24 h area under the plasma concentration-time curve calculation in patients who received intravenous vancomycin in an acute care setting.
    Chanapiwat P; Paiboonvong T; Rattanaumpawan P; Montakantikul P
    Pharmacol Res Perspect; 2023 Feb; 11(1):e01046. PubMed ID: 36588162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: A retrospective study based on electronic medical records.
    Chen Q; Wan J; Shen W; Lin W; Lin X; Huang Z; Lin M; Chen Y
    Pediatr Neonatol; 2022 May; 63(3):247-254. PubMed ID: 35190273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
    Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
    Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
    Waineo MF; Kuhn TC; Brown DL
    J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of an online calculator's vancomycin dosing and exposure appropriateness in persons who inject drugs with methicillin-resistant Staphylococcus aureus bloodstream infections.
    Opitz BJ; Housman ST; Housman EL; Lorenzo MP
    J Clin Pharm Ther; 2022 Jun; 47(6):752-758. PubMed ID: 34981545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of an AUC
    Chavada R; Ghosh N; Sandaradura I; Maley M; Van Hal SJ
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.
    Slavik RS; Jewesson PJ
    Clin Pharmacokinet; 2003; 42(9):793-817. PubMed ID: 12882587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Gawronski KM; Goff DA; Brown J; Khadem TM; Bauer KA
    Clin Ther; 2013 Jun; 35(6):772-9. PubMed ID: 23795575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost comparison of AUC:MIC- versus trough-based vancomycin monitoring for MRSA bacteremia.
    Beccari MV; Seabury RW; Mogle BT; Kufel WD; Miller CD; Steele JM
    J Am Pharm Assoc (2003); 2020; 60(5):729-733. PubMed ID: 32224054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Therapeutic Vancomycin Monitoring in Taiwan.
    Chen TT; Liu MP; Sun HC
    Microbiol Spectr; 2022 Apr; 10(2):e0156221. PubMed ID: 35412391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.
    Frymoyer A; Hersh AL; Benet LZ; Guglielmo BJ
    Pediatr Infect Dis J; 2009 May; 28(5):398-402. PubMed ID: 19295465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.
    Moise-Broder PA; Forrest A; Birmingham MC; Schentag JJ
    Clin Pharmacokinet; 2004; 43(13):925-42. PubMed ID: 15509186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing.
    Tang Z; Guan J; Li J; Yu Y; Qian M; Cao J; Shuai W; Jiao Z
    Int J Antimicrob Agents; 2021 Mar; 57(3):106300. PubMed ID: 33567334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward Model-Based Informed Precision Dosing of Vancomycin in Hematologic Cancer Patients: A First Step.
    Le Blanc J; Projean D; Savignac S; Léveillé S; Ducas MP; Brisebois-Boyer A; Marsot A
    Clin Pharmacokinet; 2024 Feb; 63(2):183-196. PubMed ID: 38127240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.